Key Takeaways
- • Enveda closed a $311 million Series E financing round led by Catalio Capital Management, bringing total capital raised to over $845 million since inception.
- • The round attracted a diverse investor base including Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital (Citadel), T. Rowe Price Investment Management accounts, and a notable sovereign wealth fund, alongside existing backers.
- • George Petrocheilos, Co-Founder and Managing Partner of Catalio Capital Management, joined Enveda's Board of Directors as part of the financing.
- • The capital raise follows two positive early clinical readouts in 2026 for medicines discovered using Enveda's PRISM platform in atopic dermatitis and metabolic health indications.
- • Enveda will deploy capital to advance multiple programs through clinical development and execute pipeline and platform expansion strategies.
Summary
Enveda, a Boulder-based clinical-stage biotechnology company, announced the completion of a $311 million Series E funding round led by Catalio Capital Management. The financing reflects strong institutional confidence in the company's AI-driven drug discovery platform and recent clinical progress.
The round assembled a prominent investor consortium spanning established venture capital firms, growth-stage investors, and institutional allocators. New investors include Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital (a Citadel company), accounts advised by T. Rowe Price Investment Management, Digitalis Ventures, a sovereign wealth fund participant, and Alderline Group. The financing was supported by existing shareholders including Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital, and Lux Capital.
The investment comes on the heels of two positive early clinical readouts delivered in 2026 for compounds discovered through Enveda's PRISM platform. Results were generated across two key therapeutic areas: atopic dermatitis and metabolic health. These clinical validation milestones appear to have provided meaningful support for the funding round, demonstrating progress beyond preclinical and early-stage research phases.
With this round, Enveda has now raised more than $845 million in total capital since its inception. Management intends to deploy proceeds to advance multiple drug candidates through clinical development stages and to scale both the pipeline and underlying technology platform. George Petrocheilos, Co-Founder and Managing Partner of Catalio Capital Management, has joined Enveda's Board of Directors, signaling continued engagement from the lead investor through governance participation.
The round assembled a prominent investor consortium spanning established venture capital firms, growth-stage investors, and institutional allocators. New investors include Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital (a Citadel company), accounts advised by T. Rowe Price Investment Management, Digitalis Ventures, a sovereign wealth fund participant, and Alderline Group. The financing was supported by existing shareholders including Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital, and Lux Capital.
The investment comes on the heels of two positive early clinical readouts delivered in 2026 for compounds discovered through Enveda's PRISM platform. Results were generated across two key therapeutic areas: atopic dermatitis and metabolic health. These clinical validation milestones appear to have provided meaningful support for the funding round, demonstrating progress beyond preclinical and early-stage research phases.
With this round, Enveda has now raised more than $845 million in total capital since its inception. Management intends to deploy proceeds to advance multiple drug candidates through clinical development stages and to scale both the pipeline and underlying technology platform. George Petrocheilos, Co-Founder and Managing Partner of Catalio Capital Management, has joined Enveda's Board of Directors, signaling continued engagement from the lead investor through governance participation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.